Lobbying Information
Subject Matters
- Health
- Industry
- Intellectual Property
- International Trade
- Research and Development
- Science and Technology
Subject Matter Details
Policies or Program
- Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
- Health care system policies or programs with respect to pharmaceuticals
- Innovation Strategy led by Industry, Science and Economic Development Canada, particularly with respect to the life sciences priority under the Innovation Strategy
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
- Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
- Patented Medicine Prices Review Board with respect to regulations of reporting obligations of patentees
- Patented Medicine Prices Review Board with respect to the regulation of pricing of patented drug products
Regulation
- Food and Drug Regulations specifically with respect to approval, regulation and life-cycle management of therapeutic products
- Food and Drug Regulations with respect to Data Protection under. C.08.004
- Patent Act regulations as they relate to the regulation of intellectual property for therapeutic products and the Patented Medicines (Notice of Compliance) Regulations
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
55 Metcalfe Street - Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Ext.
226
Client representative
Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance
Parent Company Information
Innovative Medicines Canada is not a subsidiary of any other parent companies.
Coalition Members Information
Innovative Medicines Canada is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Innovative Medicines Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Innovative Medicines Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
Stephen Sampson
|
Public offices held
Business address:
50 O'Connor St., Suite 901
Ottawa, ON K1P 6L2
Canada
Telephone number:
613-782-2336
Consultant Firm and Address
Firm:
Global Public Affairs
Address:
50 O'Connor St., Suite 901
Ottawa, ON K1P 6L2
Canada
Telephone number:
613-782-2336
